Sinopharm: COVID-19 trials

The registry lists 23 COVID-19 studies with Sinopharm as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 7Phase 3 4Phase 4 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical TrialStatus unknownNCT05599516Phase 3
• Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis PopulationStatus unknownNCT05480436Phase 4
• Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and AboveCompletedNCT05408312Phase 1
• Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and AboveActive, not recruitingNCT05382871Phase 3
• A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19Status unknownNCT05381519Phase 2
• Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and AboveActive, not recruitingNCT05374954Phase 3
• A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and AboveActive, not recruitingNCT05365724Phase 1/2
• A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)Status unknownNCT05293548Phase 2
• Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 PatientsStatus unknownNCT05173441Phase 2
• Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or DiabetesStatus unknownNCT05104437Phase 4
• Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or DiabetesStatus unknownNCT05104333Phase 4
• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPDStatus unknownNCT05075083Phase 4
• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV InfectedStatus unknownNCT05075070Phase 4
• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPDStatus unknownNCT05075057Phase 4
• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV InfectedStatus unknownNCT05075044Phase 4
• Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus unknownNCT05069129Phase 1/2
• Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or DiabetesStatus unknownNCT05065892Phase 4
• Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or DiabetesCompletedNCT05065879Phase 4
• Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus unknownNCT05033847Phase 2
• Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and AboveCompletedNCT04917523Phase 3
• A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19CompletedNCT04869592Phase 1/2
• A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), InactivatedActive, not recruitingNCT04863638Phase 4
• Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4CompletedNCT04790851Phase 4